Health Care & Life Sciences » Pharmaceuticals | Zynerba Pharmaceuticals Inc.

Zynerba Pharmaceuticals Inc.

Zynerba Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
17.62 M
Public Float
11.46 M
Zynerba Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$2.27
Market Cap
$325.4 M
Shares Outstanding
21.07 M
Public Float
14.68 M

Profile

Address
80 West Lancaster Avenue
Devon Pennsylvania 19333
United States
Employees -
Website http://zynerba.com
Updated 07/08/2019
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. The company was founded by Audra L.

Financials

View All
Created with Highcharts 5.0.14Zynerba Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.6366365 6695 66912 55112 55123 38823 38832 01232 01239 91139 911201320142015201620172018010k20k30k40k50k
Created with Highcharts 5.0.14Zynerba Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.9439438108102782787700868620132014201520162017201802505007501000

Armando Anido
Chairman & Chief Executive Officer
John P. Butler
Director